A Comparison of Near-Infrared Diffuse Optical Imaging and <sup>18</sup>F-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy

Jiang, Shudong; Pogue, Brian W.

doi:10.2967/jnumed.116.174367

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with DOI of breast cancer (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(45)(46)(47)(48)(49), the MSOT patterns were found showcasing the merits of the superior optoacoustic resolution. DOI cannot observe vascularization patterns, due to the strong photon scattering in tissue and the low resolution achieved.…”

Section: Discussionmentioning

confidence: 99%

Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer

Diot

Metz

Noske

et al. 2017

Clinical Cancer Research

218

229

View full text Add to dashboard Cite

In a pilot study, we introduce fast handheld multispectral optoacoustic tomography (MSOT) of the breast at 28 wavelengths, aiming to identify high-resolution optoacoustic (photoacoustic) patterns of breast cancer and noncancerous breast tissue. We imaged 10 female patients ages 48-81 years with malignant nonspecific breast cancer or invasive lobular carcinoma. Three healthy volunteers ages 31-36 years were also imaged. Fast-MSOT was based on unique single-frame-per-pulse (SFPP) image acquisition employed to improve the accuracy of spectral differentiation over using a small number of wavelengths. Breast tissue was illuminated at the 700-970 nm spectral range over 0.56 seconds total scan time. MSOT data were guided by ultrasonography and X-ray mammography or MRI. The extended spectral range allowed the computation of oxygenated hemoglobin (HBO), deoxygenated hemoglobin (HB), total blood volume (TBV), lipid, and water contributions, allowing first insights into high-resolution breast tissue MSOT cancer patterns. TBV and Hb/HBO images resolved marked differences between cancer and control tissue, manifested as a vessel-rich tumor periphery with highly heterogeneous spatial appearance compared with healthy tissue. We observe significant TBV variations between different tumors and between tumors over healthy tissues. Water and fat lipid layers appear disrupted in cancer versus healthy tissue; however, offer weaker contrast compared with TBV images. In contrast to optical methods, MSOT resolves physiologic cancer features with high resolution and revealed patterns not offered by other radiologic modalities. The new features relate to personalized and precision medicine potential. .

show abstract

Section: Discussionmentioning

confidence: 99%

Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer

Diot

Metz

Noske

et al. 2017

Clinical Cancer Research

218

229

View full text Add to dashboard Cite

show abstract

“…Diffuse optical tomography (DOT) and spectroscopy using near-infrared (NIR) diffused light have been explored to predict and monitor tumor vasculature response to NAC. 15 – 27 The NIR technique utilizes intrinsic hemoglobin contrast, which is directly related to tumor angiogenesis. It is particularly effective in mapping earlier tumor angiogenesis changes during NAC.…”

Section: Introductionmentioning

confidence: 99%

Ultrasound and diffuse optical tomography-transformer model for assessing pathological complete response to neoadjuvant chemotherapy in breast cancer

Zou,

Xue,

Hossain

et al. 2024

J. Biomed. Opt.

View full text Add to dashboard Cite

. Significance We evaluate the efficiency of integrating ultrasound (US) and diffuse optical tomography (DOT) images for predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients. The ultrasound-diffuse optical tomography (USDOT)-Transformer model represents a significant step toward accurate prediction of pCR, which is critical for personalized treatment planning. Aim We aim to develop and assess the performance of the USDOT-Transformer model, which combines US and DOT images with tumor receptor biomarkers to predict the pCR of breast cancer patients under NAC. Approach We developed the USDOT-Transformer model using a dual-input transformer to process co-registered US and DOT images along with tumor receptor biomarkers. Our dataset comprised imaging data from 60 patients at multiple time points during their chemotherapy treatment. We used fivefold cross-validation to assess the model’s performance, comparing its results against a single modality of US or DOT. Results The USDOT-Transformer model demonstrated excellent predictive performance, with a mean area under the receiving characteristic curve of 0.96 (95%CI: 0.93 to 0.99) across the fivefold cross-validation. The integration of US and DOT images significantly enhanced the model’s ability to predict pCR, outperforming models that relied on a single imaging modality (0.87 for US and 0.82 for DOT). This performance indicates the potential of advanced deep learning techniques and multimodal imaging data for improving the accuracy (ACC) of pCR prediction. Conclusion The USDOT-Transformer model offers a promising non-invasive approach for predicting pCR to NAC in breast cancer patients. By leveraging the structural and functional information from US and DOT images, the model offers a faster and more reliable tool for personalized treatment planning. Future work will focus on expanding the dataset and refining the model to further improve its accuracy and generalizability.

show abstract

Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography

Zhu

Ademuyiwa

Young

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background:Neoadjuvant Therapy (NAT) permits less aggressive breast and axillary surgery and better assessment of systemic response. Establishing accurate and early predictors of NAT response would help limit morbidity of ineffective regimens through modi cation of treatment regimens and thereby optimize clinical outcomes. The purpose of the study was to assess the utility of tumor biomarkers, ultrasound (US) and US-guided diffuse optical tomography (DOT) in early prediction of breast cancer response to NAT. MethodsThis prospective HIPAA compliant study was approved by the institutional review board. Forty one patients were imaged with US and US-guided DOT prior to NAT, at completion of the rst three treatment cycles, and prior to de nitive surgery from February 2017 to January 2020. Miller-Payne grading was used to assess pathologic response. Receiver operating characteristic curves (ROCs) were derived from logistic regression using independent variables, including: tumor biomarkers, US maximum diameter, percentage reduction of the diameter (%US), pretreatment maximum total hemoglobin concentration (HbT) and percentage reduction in HbT (%HbT) at different treatment time points. Resulting ROCs were compared using area under the curve (AUC). Statistical signi cance was tested using two-sided two-sample student t-test with P<0.05 considered statistically signi cant. ResultsThirty-eight patients (mean age =47, range 24-71 years) successfully completed the study, including 15 HER2+ of which 11 were ER+; 12 ER+ or PR+/HER2-, and 11 triple negative. The combination of HER2 and ER biomarkers, %HbT at the end of cycle 1 (EOC1) and %US (EOC1) provided the best early prediction, AUC = 0.941 (95% CI: 0.869-1.0). Similarly an AUC of 0.910 (95% CI: 0.810-1.0) with %US (EOC1) and %HbT (EOC1) can be achieved independent of HER2 and ER status. The most accurate prediction, AUC = 0.974 (95% CI: 0.933-1.0), was achieved with %US at EOC1 and %HbT (EOC3) independent of biomarker status. ConclusionThe combined use of tumor HER2 and ER status, US, and US-guided DOT may provide accurate prediction of NAT response as early as the completion of the rst treatment cycle.

show abstract

A Comparison of Near-Infrared Diffuse Optical Imaging and ¹⁸F-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy

Cited by 5 publications

References 9 publications

Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer

Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer

Ultrasound and diffuse optical tomography-transformer model for assessing pathological complete response to neoadjuvant chemotherapy in breast cancer

Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography

Contact Info

Product

Resources

About

A Comparison of Near-Infrared Diffuse Optical Imaging and 18F-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy

Cited by 5 publications

References 9 publications

Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer

Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer

Ultrasound and diffuse optical tomography-transformer model for assessing pathological complete response to neoadjuvant chemotherapy in breast cancer

Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography

Contact Info

Product

Resources

About

A Comparison of Near-Infrared Diffuse Optical Imaging and ¹⁸F-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy